Current Treatment Landscape of Nasopharyngeal Carcinoma and Potential Trials Evaluating the Value of Immunotherapy
Cet article résume les principaux points abordés en février 2018 aux Etats-Unis lors d'une réunion d'experts (chercheurs, cancérologues, radiothérapeutes, industriels, ...) portant sur la planification d'éventuels essais cliniques de phase II ou III évaluant des immunothérapies pour traiter un carcinome rhinopharyngé, puis propose une feuille de route pour la mise en place de futurs essais intégrant des inhibiteurs de points de contrôle immunitaire
Nasopharyngeal carcinoma (NPC) is a type of head and neck cancer with a distinctive regional and racial prevalence. It is associated with Epstein Barr Virus infection and has a high propensity for regional and distant metastases, while at the same time it is very sensitive to radiation and chemotherapy. A common feature of Epstein Barr Virus-positive NPC is the dense infiltration of lymphocytes in the tumor stroma and positive PD-L1 expression in tumor cells, making it an attractive target for immunotherapy, especially immune checkpoint inhibitors. As new immunotherapeutic agents are being rapidly adopted in many cancers, including head and neck cancer, the National Cancer Institute sponsored a Clinical Trial Planning Meeting to identify opportunities for developing phase II and III trials testing immunotherapy in different stages of NPC. The meeting started with the summary of the biology of the disease, current standards of care and evidence of immunotherapy in this cancer. Three subcommittees were tasked to develop clinical trials: loco-regionally advanced, non-metastatic NPC; widely metastatic NPC; and either local-recurrence after initial treatment or presenting with oligometastatic disease. This article summarizes the proceedings of this Clinical Trial Planning Meeting and provides a roadmap for future trials incorporating immune checkpoint inhibitors for therapeutic management of NPC. This roadmap, though specific for NPC, may also be applicable to other virally-driven cancers that have similar ability to evade the host’s immune system.
Journal of the National Cancer Institute , résumé, 2018